Emerging Targets for Drug Addiction Treatment:
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Hauppauge
Nova Science Publishers, Inc.
2012
|
Schriftenreihe: | Substance Abuse Assessment, Interventions and Treatment
|
Schlagworte: | |
Online-Zugang: | FAW01 FAW02 |
Beschreibung: | Chapter 6: PSYCHOSOCIAL AND PHARMACOLOGICAL TREATMENTS FOR BEHAVIORAL ADDICTIONS. EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine) 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES. 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES. Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES. In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t |
Beschreibung: | 240 pages |
ISBN: | 9781620819548 1620819546 9781620819135 1620819139 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV043778827 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 160920s2012 |||| o||u| ||||||eng d | ||
020 | |a 9781620819548 |9 978-1-62081-954-8 | ||
020 | |a 1620819546 |9 1-62081-954-6 | ||
020 | |a 9781620819135 |9 978-1-62081-913-5 | ||
020 | |a 1620819139 |9 1-62081-913-9 | ||
035 | |a (ZDB-4-EBA)ocn898103608 | ||
035 | |a (OCoLC)898103608 | ||
035 | |a (DE-599)BVBBV043778827 | ||
040 | |a DE-604 |b ger |e aacr | ||
041 | 0 | |a eng | |
049 | |a DE-1046 |a DE-1047 | ||
082 | 0 | |a 362.29 | |
082 | 0 | |a 616.86 | |
100 | 1 | |a Canales, Juan |e Verfasser |4 aut | |
245 | 1 | 0 | |a Emerging Targets for Drug Addiction Treatment |
264 | 1 | |a Hauppauge |b Nova Science Publishers, Inc. |c 2012 | |
300 | |a 240 pages | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
490 | 0 | |a Substance Abuse Assessment, Interventions and Treatment | |
500 | |a Chapter 6: PSYCHOSOCIAL AND PHARMACOLOGICAL TREATMENTS FOR BEHAVIORAL ADDICTIONS. | ||
500 | |a EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine) | ||
500 | |a 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy | ||
500 | |a 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES. | ||
500 | |a 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES. | ||
500 | |a Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES. | ||
500 | |a In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t | ||
650 | 4 | |a Drug addiction / Treatment | |
650 | 4 | |a Drug addiction | |
650 | 7 | |a PSYCHOLOGY / Psychopathology / Addiction |2 bisacsh | |
650 | 7 | |a SELF-HELP / Substance Abuse & Addictions / General |2 bisacsh | |
650 | 7 | |a Drug addiction / Treatment |2 fast | |
650 | 4 | |a Drug addiction |x Treatment | |
912 | |a ZDB-4-EBA | ||
999 | |a oai:aleph.bib-bvb.de:BVB01-029189887 | ||
966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext |
Datensatz im Suchindex
_version_ | 1804176607065145344 |
---|---|
any_adam_object | |
author | Canales, Juan |
author_facet | Canales, Juan |
author_role | aut |
author_sort | Canales, Juan |
author_variant | j c jc |
building | Verbundindex |
bvnumber | BV043778827 |
collection | ZDB-4-EBA |
ctrlnum | (ZDB-4-EBA)ocn898103608 (OCoLC)898103608 (DE-599)BVBBV043778827 |
dewey-full | 362.29 616.86 |
dewey-hundreds | 300 - Social sciences 600 - Technology (Applied sciences) |
dewey-ones | 362 - Social problems and services to groups 616 - Diseases |
dewey-raw | 362.29 616.86 |
dewey-search | 362.29 616.86 |
dewey-sort | 3362.29 |
dewey-tens | 360 - Social problems and services; associations 610 - Medicine and health |
discipline | Soziologie Medizin |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05323nmm a2200529zc 4500</leader><controlfield tag="001">BV043778827</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160920s2012 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781620819548</subfield><subfield code="9">978-1-62081-954-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1620819546</subfield><subfield code="9">1-62081-954-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781620819135</subfield><subfield code="9">978-1-62081-913-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1620819139</subfield><subfield code="9">1-62081-913-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-EBA)ocn898103608</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)898103608</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043778827</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.29</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.86</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Canales, Juan</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Emerging Targets for Drug Addiction Treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hauppauge</subfield><subfield code="b">Nova Science Publishers, Inc.</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">240 pages</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Substance Abuse Assessment, Interventions and Treatment</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Chapter 6: PSYCHOSOCIAL AND PHARMACOLOGICAL TREATMENTS FOR BEHAVIORAL ADDICTIONS.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine)</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug addiction / Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug addiction</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSYCHOLOGY / Psychopathology / Addiction</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SELF-HELP / Substance Abuse & Addictions / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug addiction / Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug addiction</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029189887</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV043778827 |
illustrated | Not Illustrated |
indexdate | 2024-07-10T07:34:52Z |
institution | BVB |
isbn | 9781620819548 1620819546 9781620819135 1620819139 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029189887 |
oclc_num | 898103608 |
open_access_boolean | |
owner | DE-1046 DE-1047 |
owner_facet | DE-1046 DE-1047 |
physical | 240 pages |
psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
publishDate | 2012 |
publishDateSearch | 2012 |
publishDateSort | 2012 |
publisher | Nova Science Publishers, Inc. |
record_format | marc |
series2 | Substance Abuse Assessment, Interventions and Treatment |
spelling | Canales, Juan Verfasser aut Emerging Targets for Drug Addiction Treatment Hauppauge Nova Science Publishers, Inc. 2012 240 pages txt rdacontent c rdamedia cr rdacarrier Substance Abuse Assessment, Interventions and Treatment Chapter 6: PSYCHOSOCIAL AND PHARMACOLOGICAL TREATMENTS FOR BEHAVIORAL ADDICTIONS. EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine) 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES. 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES. Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES. In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t Drug addiction / Treatment Drug addiction PSYCHOLOGY / Psychopathology / Addiction bisacsh SELF-HELP / Substance Abuse & Addictions / General bisacsh Drug addiction / Treatment fast Drug addiction Treatment |
spellingShingle | Canales, Juan Emerging Targets for Drug Addiction Treatment Drug addiction / Treatment Drug addiction PSYCHOLOGY / Psychopathology / Addiction bisacsh SELF-HELP / Substance Abuse & Addictions / General bisacsh Drug addiction / Treatment fast Drug addiction Treatment |
title | Emerging Targets for Drug Addiction Treatment |
title_auth | Emerging Targets for Drug Addiction Treatment |
title_exact_search | Emerging Targets for Drug Addiction Treatment |
title_full | Emerging Targets for Drug Addiction Treatment |
title_fullStr | Emerging Targets for Drug Addiction Treatment |
title_full_unstemmed | Emerging Targets for Drug Addiction Treatment |
title_short | Emerging Targets for Drug Addiction Treatment |
title_sort | emerging targets for drug addiction treatment |
topic | Drug addiction / Treatment Drug addiction PSYCHOLOGY / Psychopathology / Addiction bisacsh SELF-HELP / Substance Abuse & Addictions / General bisacsh Drug addiction / Treatment fast Drug addiction Treatment |
topic_facet | Drug addiction / Treatment Drug addiction PSYCHOLOGY / Psychopathology / Addiction SELF-HELP / Substance Abuse & Addictions / General Drug addiction Treatment |
work_keys_str_mv | AT canalesjuan emergingtargetsfordrugaddictiontreatment |